Op-Ed: “The Commission presents the EU’s Pharmaceutical Strategy: a paradigm shift?” by Sabrina Röttger-Wirtz
Presenting a Pharmaceutical Strategy for Europe in the middle of a pandemic has moved the European Commission into the spotlight in an area that otherwise is probably more of a niche topic in the EU law and policy community. Still, it should be clarified that the Pharmaceutical Strategy is not a reaction to the COVID-19 crisis: many of the action points contained in the Strategy can be traced back to the mission letter that President von der Leyen provided Commissioner Kyriakides with in September 2019. However, while reforms of the regulatory framework were to be expected, the COVID-19 pandemic has certainly been a catalyst for the Commission initiatives in this area.
The key action points of the Pharmaceutical Strategy are not s